EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Combined Biomarker That Includes Plasma Fibroblast Growth Factor 23, Erythropoietin, and Klotho Predicts Short- and Long-Term Morbimortality and Development of Chronic Kidney Disease in Critical Care Patients with Sepsis: A Prospective Cohort

Luis Toro, Verónica Rojas, Carolina Conejeros, Patricia Ayala, Alfredo Parra-Lucares, Francisca Ahumada, Paula Almeida, María Fernanda Silva, Karin Bravo, Catalina Pumarino, Ana María Tong, María Eugenia Pinto und 2 weitere

Biomolecules · 03.10.2023 · 13 (10) · 1481

DOI: 10.3390/biom13101481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 03.10.2023. Verfasst von Luis Toro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380456, Chile. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Erythropoietin, Acute Kidney Injury, Sepsis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo (ANID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute Kidney Injury (AKI) is a frequent complication in intensive care unit (ICU) patients that increases mortality and chronic kidney disease (CKD) development. AKI is associated with elevated plasma fibroblast growth factor 23 (FGF23), which can be modulated by erythropoietin (EPO) and Klotho. We aimed to evaluate whether a combined biomarker that includes these molecules predicted short-/long-term outcomes. We performed a prospective cohort of ICU patients with sepsis and previously normal renal function. They were followed during their inpatient stay and for one year after admission. We measured plasma FGF23, EPO, and Klotho levels at admission and calculated a combined biomarker (FEK). A total of 164 patients were recruited. Of these, 50 (30.5%) had AKI at admission, and 55 (33.5%) developed AKI within 48 h. Patients with AKI at admission and those who developed AKI within 48 h had 12- and 5-fold higher FEK values than non-AKI patients, respectively. Additionally, patients with higher FEK values had increased 1-year mortality (41.9% vs. 18.6%, p = 0.003) and CKD progression (26.2% vs. 8.3%, p = 0.023). Our data suggest that the FEK indicator predicts the risk of AKI, short-/long-term mortality, and CKD progression in ICU patients with sepsis. This new indicator can improve clinical outcome prediction and guide early therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicErythropoietinAcute Kidney InjurySepsisHumansProspective StudiesFibroblast Growth Factor-23Critical CareBiomarkers

Stichwörter der Autor:innen

acute kidney injurychronic renal insufficiencycohort studiesmortalitysepsis

Substanzen

Fibroblast Growth Factor-23ErythropoietinBiomarkers

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380456, Chile.
  • Centro de Investigación Clínica Avanzada, Hospital Clínico Universidad de Chile, Santiago 8380456, Chile.
  • Centro de Pacientes Críticos, Clinica Las Condes, Santiago 7591047, Chile.
  • Unidad de Pacientes Críticos, Departamento de Medicina, Hospital Clínico Universidad de Chile, Santiago 8380456, Chile.
  • Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8380456, Chile.
  • Clinical Laboratory, Hospital Clínico Universidad de Chile, Santiago 8380456, Chile.

Förderung

  • Agencia Nacional de Investigación y Desarrollo (ANID)

Zitieren

APA

Toro, L., Rojas, V., Conejeros, C., Ayala, P., Parra-Lucares, A., Ahumada, F., Almeida, P., Silva, M. F., Bravo, K., Pumarino, C., Tong, A. M., Pinto, M. E., Romero, C., & Michea, L. (2023). A Combined Biomarker That Includes Plasma Fibroblast Growth Factor 23, Erythropoietin, and Klotho Predicts Short- and Long-Term Morbimortality and Development of Chronic Kidney Disease in Critical Care Patients with Sepsis: A Prospective Cohort. Biomolecules, 13(10), 1481. https://doi.org/10.3390/biom13101481

Vancouver

Toro L, Rojas V, Conejeros C, Ayala P, Parra-Lucares A, Ahumada F, et al. A Combined Biomarker That Includes Plasma Fibroblast Growth Factor 23, Erythropoietin, and Klotho Predicts Short- and Long-Term Morbimortality and Development of Chronic Kidney Disease in Critical Care Patients with Sepsis: A Prospective Cohort. Biomolecules. 2023;13(10):1481. doi:10.3390/biom13101481

BibTeX
@article{Toro2023,
  author = {Toro, Luis and Rojas, Verónica and Conejeros, Carolina and Ayala, Patricia and Parra-Lucares, Alfredo and Ahumada, Francisca and Almeida, Paula and Silva, María Fernanda and Bravo, Karin and Pumarino, Catalina and Tong, Ana María and Pinto, María Eugenia and Romero, Carlos and Michea, Luis},
  title = {A Combined Biomarker That Includes Plasma Fibroblast Growth Factor 23, Erythropoietin, and Klotho Predicts Short- and Long-Term Morbimortality and Development of Chronic Kidney Disease in Critical Care Patients with Sepsis: A Prospective Cohort},
  journal = {Biomolecules},
  year = {2023},
  volume = {13},
  number = {10},
  pages = {1481},
  doi = {10.3390/biom13101481}
}
Kostenlos starten →